nodes	percent_of_prediction	percent_of_DWPC	metapath
Flutamide—CYP1B1—Doxorubicin—thyroid cancer	0.233	0.376	CbGbCtD
Flutamide—CYP3A5—Sorafenib—thyroid cancer	0.101	0.163	CbGbCtD
Flutamide—CYP2C19—Sorafenib—thyroid cancer	0.0815	0.132	CbGbCtD
Flutamide—CYP1A2—Sorafenib—thyroid cancer	0.0752	0.121	CbGbCtD
Flutamide—CYP3A4—Vandetanib—thyroid cancer	0.0654	0.106	CbGbCtD
Flutamide—CYP3A4—Sorafenib—thyroid cancer	0.0394	0.0636	CbGbCtD
Flutamide—CYP3A4—Doxorubicin—thyroid cancer	0.0239	0.0386	CbGbCtD
Flutamide—Chromaturia—Vandetanib—thyroid cancer	0.0147	0.0559	CcSEcCtD
Flutamide—Carcinoma—Sorafenib—thyroid cancer	0.0117	0.0446	CcSEcCtD
Flutamide—AHR—Aryl Hydrocarbon Receptor—RET—thyroid cancer	0.00972	0.0826	CbGpPWpGaD
Flutamide—Interstitial lung disease—Vandetanib—thyroid cancer	0.00742	0.0282	CcSEcCtD
Flutamide—Metastatic neoplasm—Epirubicin—thyroid cancer	0.00683	0.026	CcSEcCtD
Flutamide—Metastatic neoplasm—Doxorubicin—thyroid cancer	0.00632	0.024	CcSEcCtD
Flutamide—Proctitis—Epirubicin—thyroid cancer	0.00536	0.0204	CcSEcCtD
Flutamide—Cystitis noninfective—Vandetanib—thyroid cancer	0.00513	0.0195	CcSEcCtD
Flutamide—Cystitis—Vandetanib—thyroid cancer	0.00507	0.0193	CcSEcCtD
Flutamide—Interstitial lung disease—Sorafenib—thyroid cancer	0.005	0.019	CcSEcCtD
Flutamide—AR—Coregulation of Androgen receptor activity—NCOA4—thyroid cancer	0.005	0.0425	CbGpPWpGaD
Flutamide—Proctitis—Doxorubicin—thyroid cancer	0.00496	0.0189	CcSEcCtD
Flutamide—Neoplasm—Vandetanib—thyroid cancer	0.00475	0.018	CcSEcCtD
Flutamide—Bladder pain—Vandetanib—thyroid cancer	0.00475	0.018	CcSEcCtD
Flutamide—AR—Regulation of Androgen receptor activity—TRIM24—thyroid cancer	0.00424	0.036	CbGpPWpGaD
Flutamide—Neoplasm malignant—Sorafenib—thyroid cancer	0.00415	0.0158	CcSEcCtD
Flutamide—Dermatitis bullous—Vandetanib—thyroid cancer	0.00399	0.0152	CcSEcCtD
Flutamide—AR—Androgen receptor signaling pathway—NCOA4—thyroid cancer	0.00369	0.0314	CbGpPWpGaD
Flutamide—AR—Nuclear Receptors—THRB—thyroid cancer	0.00356	0.0303	CbGpPWpGaD
Flutamide—AR—Regulation of nuclear SMAD2/3 signaling—CITED1—thyroid cancer	0.00355	0.0302	CbGpPWpGaD
Flutamide—Bullous eruption—Epirubicin—thyroid cancer	0.00331	0.0126	CcSEcCtD
Flutamide—Neoplasm—Sorafenib—thyroid cancer	0.0032	0.0122	CcSEcCtD
Flutamide—Gynaecomastia—Sorafenib—thyroid cancer	0.00317	0.012	CcSEcCtD
Flutamide—Laboratory test abnormal—Epirubicin—thyroid cancer	0.00313	0.0119	CcSEcCtD
Flutamide—Bullous eruption—Doxorubicin—thyroid cancer	0.00306	0.0116	CcSEcCtD
Flutamide—Photosensitivity reaction—Vandetanib—thyroid cancer	0.00301	0.0114	CcSEcCtD
Flutamide—Hyperglycaemia—Vandetanib—thyroid cancer	0.00297	0.0113	CcSEcCtD
Flutamide—AHR—Circadian rythm related genes—NKX2-1—thyroid cancer	0.00291	0.0247	CbGpPWpGaD
Flutamide—Laboratory test abnormal—Doxorubicin—thyroid cancer	0.0029	0.011	CcSEcCtD
Flutamide—AR—Nuclear Receptor transcription pathway—THRB—thyroid cancer	0.00282	0.0239	CbGpPWpGaD
Flutamide—Haematuria—Vandetanib—thyroid cancer	0.0028	0.0106	CcSEcCtD
Flutamide—CYP1B1—Arachidonic acid metabolism—HPGD—thyroid cancer	0.00279	0.0237	CbGpPWpGaD
Flutamide—CYP1B1—Aryl Hydrocarbon Receptor—RET—thyroid cancer	0.00273	0.0232	CbGpPWpGaD
Flutamide—AHR—Integrated Breast Cancer Pathway—TPR—thyroid cancer	0.00236	0.02	CbGpPWpGaD
Flutamide—Toxic epidermal necrolysis—Sorafenib—thyroid cancer	0.00231	0.0088	CcSEcCtD
Flutamide—Aspartate aminotransferase increased—Sorafenib—thyroid cancer	0.00231	0.0088	CcSEcCtD
Flutamide—Transaminases increased—Epirubicin—thyroid cancer	0.00215	0.00818	CcSEcCtD
Flutamide—Erectile dysfunction—Sorafenib—thyroid cancer	0.00205	0.00778	CcSEcCtD
Flutamide—Transaminases increased—Doxorubicin—thyroid cancer	0.00199	0.00757	CcSEcCtD
Flutamide—Hypertension—Vandetanib—thyroid cancer	0.00198	0.00753	CcSEcCtD
Flutamide—Anxiety—Vandetanib—thyroid cancer	0.00195	0.0074	CcSEcCtD
Flutamide—Unspecified disorder of skin and subcutaneous tissue—Vandetanib—thyroid cancer	0.00194	0.00738	CcSEcCtD
Flutamide—Jaundice—Sorafenib—thyroid cancer	0.00193	0.00734	CcSEcCtD
Flutamide—AHR—Aryl Hydrocarbon Receptor—PTGS2—thyroid cancer	0.00191	0.0162	CbGpPWpGaD
Flutamide—CYP1B1—Endogenous sterols—RXRA—thyroid cancer	0.00187	0.0159	CbGpPWpGaD
Flutamide—Oedema—Vandetanib—thyroid cancer	0.00187	0.00712	CcSEcCtD
Flutamide—Thrombocytopenia—Vandetanib—thyroid cancer	0.00183	0.00697	CcSEcCtD
Flutamide—Skin disorder—Vandetanib—thyroid cancer	0.00182	0.00692	CcSEcCtD
Flutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—TCF7L1—thyroid cancer	0.00181	0.0154	CbGpPWpGaD
Flutamide—Herpes zoster—Epirubicin—thyroid cancer	0.00174	0.00661	CcSEcCtD
Flutamide—CYP1A1—Arachidonic acid metabolism—HPGD—thyroid cancer	0.00172	0.0146	CbGpPWpGaD
Flutamide—Insomnia—Vandetanib—thyroid cancer	0.00169	0.00644	CcSEcCtD
Flutamide—CYP1A1—Aryl Hydrocarbon Receptor—RET—thyroid cancer	0.00168	0.0143	CbGpPWpGaD
Flutamide—AHR—Adipogenesis—RXRA—thyroid cancer	0.00167	0.0142	CbGpPWpGaD
Flutamide—Decreased appetite—Vandetanib—thyroid cancer	0.00163	0.00619	CcSEcCtD
Flutamide—Fatigue—Vandetanib—thyroid cancer	0.00161	0.00614	CcSEcCtD
Flutamide—Herpes zoster—Doxorubicin—thyroid cancer	0.00161	0.00612	CcSEcCtD
Flutamide—Constipation—Vandetanib—thyroid cancer	0.0016	0.00609	CcSEcCtD
Flutamide—Liver injury—Epirubicin—thyroid cancer	0.00156	0.00591	CcSEcCtD
Flutamide—Erythema—Sorafenib—thyroid cancer	0.00155	0.00589	CcSEcCtD
Flutamide—Neoplasm malignant—Epirubicin—thyroid cancer	0.00153	0.00583	CcSEcCtD
Flutamide—AR—Nuclear Receptors—RXRA—thyroid cancer	0.00151	0.0129	CbGpPWpGaD
Flutamide—Jaundice cholestatic—Epirubicin—thyroid cancer	0.00149	0.00566	CcSEcCtD
Flutamide—AHR—Aryl Hydrocarbon Receptor—NRAS—thyroid cancer	0.00148	0.0126	CbGpPWpGaD
Flutamide—Rectal haemorrhage—Epirubicin—thyroid cancer	0.00145	0.00551	CcSEcCtD
Flutamide—Liver injury—Doxorubicin—thyroid cancer	0.00144	0.00547	CcSEcCtD
Flutamide—Anaemia—Sorafenib—thyroid cancer	0.00143	0.00544	CcSEcCtD
Flutamide—Neoplasm malignant—Doxorubicin—thyroid cancer	0.00142	0.00539	CcSEcCtD
Flutamide—CYP2C19—Arachidonic acid metabolism—HPGD—thyroid cancer	0.0014	0.0119	CbGpPWpGaD
Flutamide—Leukopenia—Sorafenib—thyroid cancer	0.00139	0.00527	CcSEcCtD
Flutamide—Ulcer—Epirubicin—thyroid cancer	0.00138	0.00526	CcSEcCtD
Flutamide—Jaundice cholestatic—Doxorubicin—thyroid cancer	0.00138	0.00524	CcSEcCtD
Flutamide—Asthenia—Vandetanib—thyroid cancer	0.00134	0.00511	CcSEcCtD
Flutamide—Rectal haemorrhage—Doxorubicin—thyroid cancer	0.00134	0.0051	CcSEcCtD
Flutamide—Hypertension—Sorafenib—thyroid cancer	0.00134	0.00508	CcSEcCtD
Flutamide—Pruritus—Vandetanib—thyroid cancer	0.00132	0.00504	CcSEcCtD
Flutamide—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	0.00131	0.00498	CcSEcCtD
Flutamide—Pulmonary embolism—Epirubicin—thyroid cancer	0.00131	0.00498	CcSEcCtD
Flutamide—Diarrhoea—Vandetanib—thyroid cancer	0.00128	0.00487	CcSEcCtD
Flutamide—Ulcer—Doxorubicin—thyroid cancer	0.00128	0.00487	CcSEcCtD
Flutamide—Cystitis noninfective—Epirubicin—thyroid cancer	0.00128	0.00486	CcSEcCtD
Flutamide—AHR—Aryl Hydrocarbon Receptor—KRAS—thyroid cancer	0.00128	0.0108	CbGpPWpGaD
Flutamide—CYP1B1—Metapathway biotransformation—CHST14—thyroid cancer	0.00127	0.0108	CbGpPWpGaD
Flutamide—Cystitis—Epirubicin—thyroid cancer	0.00126	0.00481	CcSEcCtD
Flutamide—AHR—Adipogenesis—HIF1A—thyroid cancer	0.00124	0.0105	CbGpPWpGaD
Flutamide—Dizziness—Vandetanib—thyroid cancer	0.00124	0.00471	CcSEcCtD
Flutamide—AR—SIDS Susceptibility Pathways—RET—thyroid cancer	0.00124	0.0105	CbGpPWpGaD
Flutamide—Thrombocytopenia—Sorafenib—thyroid cancer	0.00124	0.0047	CcSEcCtD
Flutamide—Blood urea increased—Epirubicin—thyroid cancer	0.00124	0.0047	CcSEcCtD
Flutamide—Skin disorder—Sorafenib—thyroid cancer	0.00123	0.00467	CcSEcCtD
Flutamide—Pulmonary embolism—Doxorubicin—thyroid cancer	0.00121	0.0046	CcSEcCtD
Flutamide—Anorexia—Sorafenib—thyroid cancer	0.0012	0.00458	CcSEcCtD
Flutamide—AR—Nuclear Receptor transcription pathway—RXRA—thyroid cancer	0.0012	0.0102	CbGpPWpGaD
Flutamide—Vomiting—Vandetanib—thyroid cancer	0.00119	0.00453	CcSEcCtD
Flutamide—Bladder pain—Epirubicin—thyroid cancer	0.00118	0.0045	CcSEcCtD
Flutamide—Ecchymosis—Epirubicin—thyroid cancer	0.00118	0.0045	CcSEcCtD
Flutamide—Neoplasm—Epirubicin—thyroid cancer	0.00118	0.0045	CcSEcCtD
Flutamide—Cystitis noninfective—Doxorubicin—thyroid cancer	0.00118	0.0045	CcSEcCtD
Flutamide—Rash—Vandetanib—thyroid cancer	0.00118	0.00449	CcSEcCtD
Flutamide—Dermatitis—Vandetanib—thyroid cancer	0.00118	0.00449	CcSEcCtD
Flutamide—Headache—Vandetanib—thyroid cancer	0.00117	0.00446	CcSEcCtD
Flutamide—Cystitis—Doxorubicin—thyroid cancer	0.00117	0.00445	CcSEcCtD
Flutamide—AR—Regulation of Androgen receptor activity—RXRA—thyroid cancer	0.00116	0.00986	CbGpPWpGaD
Flutamide—AR—SIDS Susceptibility Pathways—THRB—thyroid cancer	0.00115	0.00978	CbGpPWpGaD
Flutamide—Blood urea increased—Doxorubicin—thyroid cancer	0.00114	0.00435	CcSEcCtD
Flutamide—Nausea—Vandetanib—thyroid cancer	0.00111	0.00423	CcSEcCtD
Flutamide—CYP3A4—Liver X Receptor Pathway—RXRA—thyroid cancer	0.00111	0.0094	CbGpPWpGaD
Flutamide—Decreased appetite—Sorafenib—thyroid cancer	0.0011	0.00418	CcSEcCtD
Flutamide—Neoplasm—Doxorubicin—thyroid cancer	0.00109	0.00416	CcSEcCtD
Flutamide—Ecchymosis—Doxorubicin—thyroid cancer	0.00109	0.00416	CcSEcCtD
Flutamide—Bladder pain—Doxorubicin—thyroid cancer	0.00109	0.00416	CcSEcCtD
Flutamide—CYP1A2—Arachidonic acid metabolism—HPGD—thyroid cancer	0.00109	0.0093	CbGpPWpGaD
Flutamide—Diabetes mellitus—Epirubicin—thyroid cancer	0.00109	0.00415	CcSEcCtD
Flutamide—Fatigue—Sorafenib—thyroid cancer	0.00109	0.00414	CcSEcCtD
Flutamide—AHR—Aryl Hydrocarbon Receptor—HRAS—thyroid cancer	0.00108	0.00922	CbGpPWpGaD
Flutamide—Constipation—Sorafenib—thyroid cancer	0.00108	0.00411	CcSEcCtD
Flutamide—CYP1A2—Aryl Hydrocarbon Receptor—RET—thyroid cancer	0.00107	0.00909	CbGpPWpGaD
Flutamide—AHR—Adipogenesis—PPARG—thyroid cancer	0.00106	0.00897	CbGpPWpGaD
Flutamide—Hot flush—Epirubicin—thyroid cancer	0.00102	0.00386	CcSEcCtD
Flutamide—Increased appetite—Epirubicin—thyroid cancer	0.00101	0.00384	CcSEcCtD
Flutamide—Diabetes mellitus—Doxorubicin—thyroid cancer	0.00101	0.00384	CcSEcCtD
Flutamide—Menopausal symptoms—Epirubicin—thyroid cancer	0.00101	0.00383	CcSEcCtD
Flutamide—Dermatitis bullous—Epirubicin—thyroid cancer	0.000994	0.00378	CcSEcCtD
Flutamide—AR—Nuclear Receptors—PPARG—thyroid cancer	0.000956	0.00812	CbGpPWpGaD
Flutamide—AR—Notch-mediated HES/HEY network—HIF1A—thyroid cancer	0.000948	0.00806	CbGpPWpGaD
Flutamide—Hot flush—Doxorubicin—thyroid cancer	0.00094	0.00357	CcSEcCtD
Flutamide—CYP3A5—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	0.000938	0.00797	CbGpPWpGaD
Flutamide—Increased appetite—Doxorubicin—thyroid cancer	0.000936	0.00356	CcSEcCtD
Flutamide—Menopausal symptoms—Doxorubicin—thyroid cancer	0.000931	0.00354	CcSEcCtD
Flutamide—Dermatitis bullous—Doxorubicin—thyroid cancer	0.00092	0.0035	CcSEcCtD
Flutamide—AHR—Integrated Breast Cancer Pathway—BRAF—thyroid cancer	0.000912	0.00775	CbGpPWpGaD
Flutamide—Asthenia—Sorafenib—thyroid cancer	0.000906	0.00345	CcSEcCtD
Flutamide—Pruritus—Sorafenib—thyroid cancer	0.000894	0.0034	CcSEcCtD
Flutamide—CYP1B1—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.00087	0.0074	CbGpPWpGaD
Flutamide—Diarrhoea—Sorafenib—thyroid cancer	0.000864	0.00329	CcSEcCtD
Flutamide—Toxic epidermal necrolysis—Epirubicin—thyroid cancer	0.000855	0.00325	CcSEcCtD
Flutamide—Aspartate aminotransferase increased—Epirubicin—thyroid cancer	0.000855	0.00325	CcSEcCtD
Flutamide—Dizziness—Sorafenib—thyroid cancer	0.000835	0.00318	CcSEcCtD
Flutamide—CYP3A5—Metapathway biotransformation—CHST14—thyroid cancer	0.000827	0.00703	CbGpPWpGaD
Flutamide—Vomiting—Sorafenib—thyroid cancer	0.000803	0.00305	CcSEcCtD
Flutamide—AR—Integrated Breast Cancer Pathway—TPR—thyroid cancer	0.000798	0.00678	CbGpPWpGaD
Flutamide—Rash—Sorafenib—thyroid cancer	0.000797	0.00303	CcSEcCtD
Flutamide—Dermatitis—Sorafenib—thyroid cancer	0.000796	0.00303	CcSEcCtD
Flutamide—Toxic epidermal necrolysis—Doxorubicin—thyroid cancer	0.000791	0.00301	CcSEcCtD
Flutamide—Aspartate aminotransferase increased—Doxorubicin—thyroid cancer	0.000791	0.00301	CcSEcCtD
Flutamide—Headache—Sorafenib—thyroid cancer	0.000791	0.00301	CcSEcCtD
Flutamide—CYP1A1—Metapathway biotransformation—CHST14—thyroid cancer	0.000782	0.00664	CbGpPWpGaD
Flutamide—AR—SIDS Susceptibility Pathways—PRKAR1A—thyroid cancer	0.000765	0.0065	CbGpPWpGaD
Flutamide—AR—Nuclear Receptor transcription pathway—PPARG—thyroid cancer	0.000755	0.00642	CbGpPWpGaD
Flutamide—Nausea—Sorafenib—thyroid cancer	0.00075	0.00285	CcSEcCtD
Flutamide—Photosensitivity reaction—Epirubicin—thyroid cancer	0.000749	0.00285	CcSEcCtD
Flutamide—AHR—Circadian rythm related genes—PPARG—thyroid cancer	0.000745	0.00633	CbGpPWpGaD
Flutamide—Hyperglycaemia—Epirubicin—thyroid cancer	0.000741	0.00282	CcSEcCtD
Flutamide—Drowsiness—Epirubicin—thyroid cancer	0.000732	0.00278	CcSEcCtD
Flutamide—CYP2C19—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	0.000725	0.00616	CbGpPWpGaD
Flutamide—Jaundice—Epirubicin—thyroid cancer	0.000714	0.00271	CcSEcCtD
Flutamide—CYP1B1—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000706	0.006	CbGpPWpGaD
Flutamide—Haematuria—Epirubicin—thyroid cancer	0.000698	0.00265	CcSEcCtD
Flutamide—Photosensitivity reaction—Doxorubicin—thyroid cancer	0.000693	0.00264	CcSEcCtD
Flutamide—Hyperglycaemia—Doxorubicin—thyroid cancer	0.000685	0.00261	CcSEcCtD
Flutamide—Drowsiness—Doxorubicin—thyroid cancer	0.000677	0.00258	CcSEcCtD
Flutamide—AR—Generic Transcription Pathway—TRIM33—thyroid cancer	0.000673	0.00572	CbGpPWpGaD
Flutamide—AHR—Integrated Breast Cancer Pathway—CCND1—thyroid cancer	0.000665	0.00565	CbGpPWpGaD
Flutamide—CYP3A4—Farnesoid X Receptor  Pathway—RXRA—thyroid cancer	0.000662	0.00562	CbGpPWpGaD
Flutamide—Jaundice—Doxorubicin—thyroid cancer	0.00066	0.00251	CcSEcCtD
Flutamide—Hepatitis—Epirubicin—thyroid cancer	0.000657	0.0025	CcSEcCtD
Flutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—TERT—thyroid cancer	0.000648	0.00551	CbGpPWpGaD
Flutamide—Oedema peripheral—Epirubicin—thyroid cancer	0.000647	0.00246	CcSEcCtD
Flutamide—Haematuria—Doxorubicin—thyroid cancer	0.000646	0.00246	CcSEcCtD
Flutamide—AHR—Integrated Breast Cancer Pathway—PTEN—thyroid cancer	0.000642	0.00546	CbGpPWpGaD
Flutamide—CYP2C19—Metapathway biotransformation—CHST14—thyroid cancer	0.00064	0.00544	CbGpPWpGaD
Flutamide—Hepatitis—Doxorubicin—thyroid cancer	0.000608	0.00231	CcSEcCtD
Flutamide—AR—SIDS Susceptibility Pathways—SST—thyroid cancer	0.000605	0.00514	CbGpPWpGaD
Flutamide—Oedema peripheral—Doxorubicin—thyroid cancer	0.000599	0.00228	CcSEcCtD
Flutamide—Erythema—Epirubicin—thyroid cancer	0.000572	0.00218	CcSEcCtD
Flutamide—CYP3A5—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.000567	0.00482	CbGpPWpGaD
Flutamide—Tension—Epirubicin—thyroid cancer	0.000561	0.00213	CcSEcCtD
Flutamide—Nervousness—Epirubicin—thyroid cancer	0.000556	0.00211	CcSEcCtD
Flutamide—CYP1A1—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.000536	0.00455	CbGpPWpGaD
Flutamide—CYP1B1—Aryl Hydrocarbon Receptor—PTGS2—thyroid cancer	0.000535	0.00454	CbGpPWpGaD
Flutamide—Ill-defined disorder—Epirubicin—thyroid cancer	0.000531	0.00202	CcSEcCtD
Flutamide—Erythema—Doxorubicin—thyroid cancer	0.000529	0.00201	CcSEcCtD
Flutamide—Anaemia—Epirubicin—thyroid cancer	0.000529	0.00201	CcSEcCtD
Flutamide—Tension—Doxorubicin—thyroid cancer	0.000519	0.00198	CcSEcCtD
Flutamide—Malaise—Epirubicin—thyroid cancer	0.000516	0.00196	CcSEcCtD
Flutamide—Nervousness—Doxorubicin—thyroid cancer	0.000514	0.00196	CcSEcCtD
Flutamide—Leukopenia—Epirubicin—thyroid cancer	0.000512	0.00195	CcSEcCtD
Flutamide—AHR—Circadian rythm related genes—PTEN—thyroid cancer	0.000511	0.00434	CbGpPWpGaD
Flutamide—AR—Nongenotropic Androgen signaling—HRAS—thyroid cancer	0.000504	0.00428	CbGpPWpGaD
Flutamide—CYP1B1—Arachidonic acid metabolism—PTGS2—thyroid cancer	0.0005	0.00425	CbGpPWpGaD
Flutamide—CYP1A2—Metapathway biotransformation—CHST14—thyroid cancer	0.000498	0.00424	CbGpPWpGaD
Flutamide—Hypertension—Epirubicin—thyroid cancer	0.000494	0.00188	CcSEcCtD
Flutamide—AHR—Integrated Breast Cancer Pathway—KRAS—thyroid cancer	0.000493	0.00419	CbGpPWpGaD
Flutamide—Ill-defined disorder—Doxorubicin—thyroid cancer	0.000491	0.00187	CcSEcCtD
Flutamide—Anaemia—Doxorubicin—thyroid cancer	0.000489	0.00186	CcSEcCtD
Flutamide—AR—Generic Transcription Pathway—THRB—thyroid cancer	0.000486	0.00413	CbGpPWpGaD
Flutamide—Anxiety—Epirubicin—thyroid cancer	0.000485	0.00185	CcSEcCtD
Flutamide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.000484	0.00184	CcSEcCtD
Flutamide—Discomfort—Epirubicin—thyroid cancer	0.000481	0.00183	CcSEcCtD
Flutamide—Malaise—Doxorubicin—thyroid cancer	0.000477	0.00182	CcSEcCtD
Flutamide—Leukopenia—Doxorubicin—thyroid cancer	0.000474	0.0018	CcSEcCtD
Flutamide—Confusional state—Epirubicin—thyroid cancer	0.000471	0.00179	CcSEcCtD
Flutamide—Oedema—Epirubicin—thyroid cancer	0.000467	0.00178	CcSEcCtD
Flutamide—AR—Coregulation of Androgen receptor activity—CCND1—thyroid cancer	0.000465	0.00395	CbGpPWpGaD
Flutamide—CYP3A5—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.00046	0.00391	CbGpPWpGaD
Flutamide—Thrombocytopenia—Epirubicin—thyroid cancer	0.000457	0.00174	CcSEcCtD
Flutamide—Hypertension—Doxorubicin—thyroid cancer	0.000457	0.00174	CcSEcCtD
Flutamide—Skin disorder—Epirubicin—thyroid cancer	0.000453	0.00172	CcSEcCtD
Flutamide—Anxiety—Doxorubicin—thyroid cancer	0.000449	0.00171	CcSEcCtD
Flutamide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.000448	0.0017	CcSEcCtD
Flutamide—Discomfort—Doxorubicin—thyroid cancer	0.000445	0.00169	CcSEcCtD
Flutamide—Anorexia—Epirubicin—thyroid cancer	0.000445	0.00169	CcSEcCtD
Flutamide—AR—Nongenotropic Androgen signaling—AKT1—thyroid cancer	0.000445	0.00378	CbGpPWpGaD
Flutamide—CYP2C19—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.000439	0.00373	CbGpPWpGaD
Flutamide—AHR—Integrated Breast Cancer Pathway—TP53—thyroid cancer	0.000438	0.00372	CbGpPWpGaD
Flutamide—CYP3A4—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	0.000436	0.00371	CbGpPWpGaD
Flutamide—Confusional state—Doxorubicin—thyroid cancer	0.000436	0.00166	CcSEcCtD
Flutamide—CYP1A1—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000434	0.00369	CbGpPWpGaD
Flutamide—Oedema—Doxorubicin—thyroid cancer	0.000432	0.00164	CcSEcCtD
Flutamide—Thrombocytopenia—Doxorubicin—thyroid cancer	0.000423	0.00161	CcSEcCtD
Flutamide—Insomnia—Epirubicin—thyroid cancer	0.000422	0.00161	CcSEcCtD
Flutamide—Skin disorder—Doxorubicin—thyroid cancer	0.00042	0.0016	CcSEcCtD
Flutamide—CYP1B1—Aryl Hydrocarbon Receptor—NRAS—thyroid cancer	0.000416	0.00353	CbGpPWpGaD
Flutamide—AR—Integrated Pancreatic Cancer Pathway—RXRA—thyroid cancer	0.000416	0.00353	CbGpPWpGaD
Flutamide—Somnolence—Epirubicin—thyroid cancer	0.000415	0.00158	CcSEcCtD
Flutamide—Anorexia—Doxorubicin—thyroid cancer	0.000412	0.00157	CcSEcCtD
Flutamide—Decreased appetite—Epirubicin—thyroid cancer	0.000406	0.00154	CcSEcCtD
Flutamide—Fatigue—Epirubicin—thyroid cancer	0.000403	0.00153	CcSEcCtD
Flutamide—Constipation—Epirubicin—thyroid cancer	0.000399	0.00152	CcSEcCtD
Flutamide—CYP1B1—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.000398	0.00339	CbGpPWpGaD
Flutamide—Insomnia—Doxorubicin—thyroid cancer	0.000391	0.00149	CcSEcCtD
Flutamide—Feeling abnormal—Epirubicin—thyroid cancer	0.000385	0.00146	CcSEcCtD
Flutamide—CYP3A4—Metapathway biotransformation—CHST14—thyroid cancer	0.000385	0.00327	CbGpPWpGaD
Flutamide—Somnolence—Doxorubicin—thyroid cancer	0.000384	0.00146	CcSEcCtD
Flutamide—Decreased appetite—Doxorubicin—thyroid cancer	0.000376	0.00143	CcSEcCtD
Flutamide—CYP1B1—Biological oxidations—RXRA—thyroid cancer	0.000375	0.00318	CbGpPWpGaD
Flutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—CCND1—thyroid cancer	0.000374	0.00318	CbGpPWpGaD
Flutamide—Fatigue—Doxorubicin—thyroid cancer	0.000372	0.00142	CcSEcCtD
Flutamide—AHR—Integrated Breast Cancer Pathway—AKT1—thyroid cancer	0.00037	0.00315	CbGpPWpGaD
Flutamide—Constipation—Doxorubicin—thyroid cancer	0.000369	0.0014	CcSEcCtD
Flutamide—AR—SIDS Susceptibility Pathways—HIF1A—thyroid cancer	0.000363	0.00309	CbGpPWpGaD
Flutamide—CYP1B1—Aryl Hydrocarbon Receptor—KRAS—thyroid cancer	0.000358	0.00304	CbGpPWpGaD
Flutamide—Feeling abnormal—Doxorubicin—thyroid cancer	0.000356	0.00135	CcSEcCtD
Flutamide—CYP2C19—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000356	0.00302	CbGpPWpGaD
Flutamide—AHR—Circadian rythm related genes—TP53—thyroid cancer	0.000349	0.00296	CbGpPWpGaD
Flutamide—AR—Androgen receptor signaling pathway—CCND1—thyroid cancer	0.000344	0.00292	CbGpPWpGaD
Flutamide—CYP1A2—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.000342	0.0029	CbGpPWpGaD
Flutamide—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	0.00034	0.00289	CbGpPWpGaD
Flutamide—Asthenia—Epirubicin—thyroid cancer	0.000335	0.00127	CcSEcCtD
Flutamide—AR—Androgen receptor signaling pathway—PTEN—thyroid cancer	0.000332	0.00282	CbGpPWpGaD
Flutamide—Pruritus—Epirubicin—thyroid cancer	0.00033	0.00126	CcSEcCtD
Flutamide—CYP1A1—PPARA activates gene expression—RXRA—thyroid cancer	0.00033	0.0028	CbGpPWpGaD
Flutamide—CYP1A1—Aryl Hydrocarbon Receptor—PTGS2—thyroid cancer	0.000329	0.0028	CbGpPWpGaD
Flutamide—AR—Gene Expression—TRIM33—thyroid cancer	0.000324	0.00275	CbGpPWpGaD
Flutamide—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—RXRA—thyroid cancer	0.000323	0.00274	CbGpPWpGaD
Flutamide—Diarrhoea—Epirubicin—thyroid cancer	0.000319	0.00121	CcSEcCtD
Flutamide—Asthenia—Doxorubicin—thyroid cancer	0.00031	0.00118	CcSEcCtD
Flutamide—AR—Generic Transcription Pathway—MEN1—thyroid cancer	0.000309	0.00262	CbGpPWpGaD
Flutamide—Dizziness—Epirubicin—thyroid cancer	0.000309	0.00117	CcSEcCtD
Flutamide—AR—Integrated Breast Cancer Pathway—BRAF—thyroid cancer	0.000309	0.00262	CbGpPWpGaD
Flutamide—CYP1A1—Arachidonic acid metabolism—PTGS2—thyroid cancer	0.000308	0.00262	CbGpPWpGaD
Flutamide—Pruritus—Doxorubicin—thyroid cancer	0.000306	0.00116	CcSEcCtD
Flutamide—CYP1B1—Aryl Hydrocarbon Receptor—HRAS—thyroid cancer	0.000304	0.00259	CbGpPWpGaD
Flutamide—Vomiting—Epirubicin—thyroid cancer	0.000297	0.00113	CcSEcCtD
Flutamide—Diarrhoea—Doxorubicin—thyroid cancer	0.000296	0.00112	CcSEcCtD
Flutamide—Rash—Epirubicin—thyroid cancer	0.000294	0.00112	CcSEcCtD
Flutamide—Dermatitis—Epirubicin—thyroid cancer	0.000294	0.00112	CcSEcCtD
Flutamide—Headache—Epirubicin—thyroid cancer	0.000292	0.00111	CcSEcCtD
Flutamide—Dizziness—Doxorubicin—thyroid cancer	0.000286	0.00109	CcSEcCtD
Flutamide—Nausea—Epirubicin—thyroid cancer	0.000277	0.00105	CcSEcCtD
Flutamide—CYP1A2—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000277	0.00235	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism—MINPP1—thyroid cancer	0.000275	0.00234	CbGpPWpGaD
Flutamide—Vomiting—Doxorubicin—thyroid cancer	0.000275	0.00104	CcSEcCtD
Flutamide—Rash—Doxorubicin—thyroid cancer	0.000272	0.00104	CcSEcCtD
Flutamide—Dermatitis—Doxorubicin—thyroid cancer	0.000272	0.00103	CcSEcCtD
Flutamide—Headache—Doxorubicin—thyroid cancer	0.000271	0.00103	CcSEcCtD
Flutamide—CYP3A4—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.000264	0.00224	CbGpPWpGaD
Flutamide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	0.000262	0.00223	CbGpPWpGaD
Flutamide—AR—Coregulation of Androgen receptor activity—AKT1—thyroid cancer	0.000259	0.0022	CbGpPWpGaD
Flutamide—Nausea—Doxorubicin—thyroid cancer	0.000257	0.000976	CcSEcCtD
Flutamide—CYP1A1—Aryl Hydrocarbon Receptor—NRAS—thyroid cancer	0.000256	0.00218	CbGpPWpGaD
Flutamide—CYP2C19—Arachidonic acid metabolism—PTGS2—thyroid cancer	0.000252	0.00214	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.000245	0.00208	CbGpPWpGaD
Flutamide—CYP3A5—Biological oxidations—RXRA—thyroid cancer	0.000244	0.00208	CbGpPWpGaD
Flutamide—AR—Gene Expression—THRB—thyroid cancer	0.000234	0.00199	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism—NDUFA13—thyroid cancer	0.000234	0.00199	CbGpPWpGaD
Flutamide—CYP1A1—Biological oxidations—RXRA—thyroid cancer	0.000231	0.00196	CbGpPWpGaD
Flutamide—AR—Integrated Breast Cancer Pathway—CCND1—thyroid cancer	0.000225	0.00191	CbGpPWpGaD
Flutamide—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—RXRA—thyroid cancer	0.000223	0.00189	CbGpPWpGaD
Flutamide—CYP1A1—Aryl Hydrocarbon Receptor—KRAS—thyroid cancer	0.00022	0.00187	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism—CHST14—thyroid cancer	0.00022	0.00187	CbGpPWpGaD
Flutamide—AR—Integrated Breast Cancer Pathway—PTEN—thyroid cancer	0.000217	0.00185	CbGpPWpGaD
Flutamide—CYP3A4—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000214	0.00182	CbGpPWpGaD
Flutamide—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—thyroid cancer	0.00021	0.00178	CbGpPWpGaD
Flutamide—CYP1A1—PPARA activates gene expression—PPARG—thyroid cancer	0.000208	0.00177	CbGpPWpGaD
Flutamide—AR—Generic Transcription Pathway—RXRA—thyroid cancer	0.000207	0.00176	CbGpPWpGaD
Flutamide—AR—Integrated Pancreatic Cancer Pathway—PTGS2—thyroid cancer	0.000207	0.00176	CbGpPWpGaD
Flutamide—AR—Regulation of nuclear SMAD2/3 signaling—AKT1—thyroid cancer	0.000206	0.00175	CbGpPWpGaD
Flutamide—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARG—thyroid cancer	0.000204	0.00173	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.000201	0.00171	CbGpPWpGaD
Flutamide—CYP1A2—Arachidonic acid metabolism—PTGS2—thyroid cancer	0.000196	0.00167	CbGpPWpGaD
Flutamide—AR—Androgen receptor signaling pathway—AKT1—thyroid cancer	0.000191	0.00163	CbGpPWpGaD
Flutamide—CYP2C19—Biological oxidations—RXRA—thyroid cancer	0.000189	0.0016	CbGpPWpGaD
Flutamide—CYP1A1—Aryl Hydrocarbon Receptor—HRAS—thyroid cancer	0.000187	0.00159	CbGpPWpGaD
Flutamide—AR—Integrated Pancreatic Cancer Pathway—CCND1—thyroid cancer	0.000187	0.00159	CbGpPWpGaD
Flutamide—AR—Integrated Pancreatic Cancer Pathway—PTEN—thyroid cancer	0.00018	0.00153	CbGpPWpGaD
Flutamide—CYP3A5—Metabolism—MINPP1—thyroid cancer	0.000179	0.00153	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism—HPGD—thyroid cancer	0.000177	0.00151	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism—MINPP1—thyroid cancer	0.00017	0.00144	CbGpPWpGaD
Flutamide—AR—Integrated Breast Cancer Pathway—KRAS—thyroid cancer	0.000167	0.00142	CbGpPWpGaD
Flutamide—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—thyroid cancer	0.000163	0.00139	CbGpPWpGaD
Flutamide—AR—Gene Expression—TPR—thyroid cancer	0.000158	0.00134	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.000156	0.00133	CbGpPWpGaD
Flutamide—CYP3A5—Metabolism—NDUFA13—thyroid cancer	0.000153	0.0013	CbGpPWpGaD
Flutamide—AR—Gene Expression—MEN1—thyroid cancer	0.000149	0.00126	CbGpPWpGaD
Flutamide—AR—Integrated Breast Cancer Pathway—TP53—thyroid cancer	0.000148	0.00126	CbGpPWpGaD
Flutamide—CYP1A2—Biological oxidations—RXRA—thyroid cancer	0.000147	0.00125	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism—NDUFA13—thyroid cancer	0.000144	0.00123	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	0.000144	0.00122	CbGpPWpGaD
Flutamide—CYP3A5—Metabolism—CHST14—thyroid cancer	0.000143	0.00122	CbGpPWpGaD
Flutamide—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—thyroid cancer	0.000141	0.00119	CbGpPWpGaD
Flutamide—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—thyroid cancer	0.000141	0.00119	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism—MINPP1—thyroid cancer	0.000139	0.00118	CbGpPWpGaD
Flutamide—AR—Integrated Pancreatic Cancer Pathway—KRAS—thyroid cancer	0.000138	0.00118	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism—CHST14—thyroid cancer	0.000136	0.00115	CbGpPWpGaD
Flutamide—AR—Generic Transcription Pathway—PPARG—thyroid cancer	0.00013	0.00111	CbGpPWpGaD
Flutamide—AR—Integrated Breast Cancer Pathway—AKT1—thyroid cancer	0.000125	0.00106	CbGpPWpGaD
Flutamide—AR—Integrated Pancreatic Cancer Pathway—TP53—thyroid cancer	0.000123	0.00104	CbGpPWpGaD
Flutamide—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—thyroid cancer	0.000119	0.00102	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism—NDUFA13—thyroid cancer	0.000118	0.001	CbGpPWpGaD
Flutamide—CYP3A5—Metabolism—HPGD—thyroid cancer	0.000116	0.000983	CbGpPWpGaD
Flutamide—CYP3A4—Biological oxidations—RXRA—thyroid cancer	0.000114	0.000965	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism—CHST14—thyroid cancer	0.000111	0.000943	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism—HPGD—thyroid cancer	0.000109	0.000928	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism—MINPP1—thyroid cancer	0.000108	0.000919	CbGpPWpGaD
Flutamide—AR—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	0.000104	0.000882	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism—TPR—thyroid cancer	0.000102	0.000866	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism—PRKAR1A—thyroid cancer	0.0001	0.000852	CbGpPWpGaD
Flutamide—AR—Gene Expression—RXRA—thyroid cancer	9.95e-05	0.000845	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism—NDUFA13—thyroid cancer	9.19e-05	0.000781	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	9.09e-05	0.000772	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism—HPGD—thyroid cancer	8.94e-05	0.00076	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	8.86e-05	0.000753	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism—CHST14—thyroid cancer	8.64e-05	0.000734	CbGpPWpGaD
Flutamide—CYP3A4—Metabolism—MINPP1—thyroid cancer	8.34e-05	0.000709	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism—SLC5A5—thyroid cancer	7.63e-05	0.000648	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	7.25e-05	0.000616	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	7.15e-05	0.000607	CbGpPWpGaD
Flutamide—CYP3A4—Metabolism—NDUFA13—thyroid cancer	7.09e-05	0.000603	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism—HPGD—thyroid cancer	6.97e-05	0.000592	CbGpPWpGaD
Flutamide—CYP3A4—Metabolism—CHST14—thyroid cancer	6.67e-05	0.000567	CbGpPWpGaD
Flutamide—CYP3A5—Metabolism—TPR—thyroid cancer	6.64e-05	0.000564	CbGpPWpGaD
Flutamide—CYP3A5—Metabolism—PRKAR1A—thyroid cancer	6.53e-05	0.000555	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism—RXRA—thyroid cancer	6.41e-05	0.000545	CbGpPWpGaD
Flutamide—AR—Gene Expression—PPARG—thyroid cancer	6.28e-05	0.000534	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism—TPR—thyroid cancer	6.28e-05	0.000533	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	6.23e-05	0.00053	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism—PRKAR1A—thyroid cancer	6.17e-05	0.000525	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	5.65e-05	0.00048	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	5.6e-05	0.000476	CbGpPWpGaD
Flutamide—CYP3A4—Metabolism—HPGD—thyroid cancer	5.38e-05	0.000457	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism—TPR—thyroid cancer	5.14e-05	0.000436	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism—PRKAR1A—thyroid cancer	5.05e-05	0.000429	CbGpPWpGaD
Flutamide—CYP3A5—Metabolism—SLC5A5—thyroid cancer	4.97e-05	0.000423	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism—SLC5A5—thyroid cancer	4.7e-05	0.000399	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	4.58e-05	0.000389	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	4.4e-05	0.000374	CbGpPWpGaD
Flutamide—CYP3A5—Metabolism—RXRA—thyroid cancer	4.18e-05	0.000355	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism—PPARG—thyroid cancer	4.05e-05	0.000344	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism—TPR—thyroid cancer	4e-05	0.00034	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism—RXRA—thyroid cancer	3.95e-05	0.000335	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism—PRKAR1A—thyroid cancer	3.94e-05	0.000335	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism—SLC5A5—thyroid cancer	3.84e-05	0.000327	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	3.84e-05	0.000326	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	3.6e-05	0.000306	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	3.57e-05	0.000303	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism—RXRA—thyroid cancer	3.23e-05	0.000274	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism—PTGS2—thyroid cancer	3.18e-05	0.000271	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	3.14e-05	0.000267	CbGpPWpGaD
Flutamide—CYP3A4—Metabolism—TPR—thyroid cancer	3.09e-05	0.000262	CbGpPWpGaD
Flutamide—CYP3A4—Metabolism—PRKAR1A—thyroid cancer	3.04e-05	0.000258	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism—SLC5A5—thyroid cancer	3e-05	0.000255	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	2.81e-05	0.000239	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism—PTEN—thyroid cancer	2.78e-05	0.000236	CbGpPWpGaD
Flutamide—CYP3A5—Metabolism—PPARG—thyroid cancer	2.64e-05	0.000224	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism—RXRA—thyroid cancer	2.52e-05	0.000214	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism—PPARG—thyroid cancer	2.49e-05	0.000212	CbGpPWpGaD
Flutamide—AR—Gene Expression—AKT1—thyroid cancer	2.48e-05	0.000211	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	2.45e-05	0.000208	CbGpPWpGaD
Flutamide—CYP3A4—Metabolism—SLC5A5—thyroid cancer	2.31e-05	0.000196	CbGpPWpGaD
Flutamide—CYP3A5—Metabolism—PTGS2—thyroid cancer	2.08e-05	0.000176	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism—PPARG—thyroid cancer	2.04e-05	0.000173	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism—PTGS2—thyroid cancer	1.96e-05	0.000167	CbGpPWpGaD
Flutamide—CYP3A4—Metabolism—RXRA—thyroid cancer	1.94e-05	0.000165	CbGpPWpGaD
Flutamide—CYP3A5—Metabolism—PTEN—thyroid cancer	1.81e-05	0.000154	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism—PTEN—thyroid cancer	1.71e-05	0.000145	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism—PTGS2—thyroid cancer	1.6e-05	0.000136	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism—AKT1—thyroid cancer	1.6e-05	0.000136	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism—PPARG—thyroid cancer	1.59e-05	0.000135	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism—PTEN—thyroid cancer	1.4e-05	0.000119	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism—PTGS2—thyroid cancer	1.25e-05	0.000106	CbGpPWpGaD
Flutamide—CYP3A4—Metabolism—PPARG—thyroid cancer	1.23e-05	0.000104	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism—PTEN—thyroid cancer	1.09e-05	9.26e-05	CbGpPWpGaD
Flutamide—CYP3A5—Metabolism—AKT1—thyroid cancer	1.04e-05	8.86e-05	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism—AKT1—thyroid cancer	9.85e-06	8.37e-05	CbGpPWpGaD
Flutamide—CYP3A4—Metabolism—PTGS2—thyroid cancer	9.65e-06	8.2e-05	CbGpPWpGaD
Flutamide—CYP3A4—Metabolism—PTEN—thyroid cancer	8.41e-06	7.15e-05	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism—AKT1—thyroid cancer	8.06e-06	6.85e-05	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism—AKT1—thyroid cancer	6.28e-06	5.34e-05	CbGpPWpGaD
Flutamide—CYP3A4—Metabolism—AKT1—thyroid cancer	4.85e-06	4.12e-05	CbGpPWpGaD
